Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06144346 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metastases Directed Therapy for Oligometastatic Breast Cancer

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 22, 2023 (before its estimated August 19, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
Trial Details
NCT Number NCT06144346
Lead Sponsor National Cancer Institute, Egypt
Conditions
(from sponsor)		 Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer
Related terms Breast Neoplasms, Neoplasm Metastasis
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov